• Suzhou Xinnovi Pharma listed on Shanghai’s STAR Market on Sept. 16 under stock code 688837.
• Chengdu High-Tech Orinno Investment Group gained exposure via a co-investment sub-fund, Chengdu DCP YJ Equity Investment Fund.
• Xinnovi reported a “1+3+N” pipeline; one drug is under NDA review, three are in Phase III or pivotal studies.
• Imipenem-cilastatin injection filing was accepted by China’s CDE in July 2025; approval is expected in 2026.
• Three oncology candidates in late-stage development carry CDE breakthrough designation; approvals are targeted for 2027-2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chengdu High-Tech Orinno Investment Group Co Ltd published the original content used to generate this news brief on September 18, 2026, and is solely responsible for the information contained therein.